Home
ALLO
ALLO News

Latest Allogene Therapeutics Inc. (ALLO) News on November 17, 2024

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

Zacks

3 days ago

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

Allogene's Q3 Loss Narrower Than Expected, Sales Nil

Zacks

9 days ago

Allogene's Q3 Loss Narrower Than Expected, Sales Nil

Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ...

GuruFocus.com

9 days ago

Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ...

Associated Press Finance

10 days ago

Allogene Therapeutics: Q3 Earnings Snapshot

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

GlobeNewswire

10 days ago

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up

Zacks

10 days ago

CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

GlobeNewswire

10 days ago

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Allogene Therapeutics Inc (ALLO) Q3 2024: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

11 days ago

Allogene Therapeutics Inc (ALLO) Q3 2024: Everything You Need To Know Ahead Of Earnings

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire

12 days ago

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Allogene Therapeutics Announces Participation in November Investor Conferences

GlobeNewswire

13 days ago

Allogene Therapeutics Announces Participation in November Investor Conferences

Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline

Zacks

16 days ago

Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline

Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know

Zacks

17 days ago

Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

GlobeNewswire

18 days ago

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

MT Newswires

19 days ago

Allogene's ALLO-316 Obtains FDA's RMAT Designation for Advanced Renal Cell Carcinoma

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Simply Wall St.

19 days ago

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

GlobeNewswire

19 days ago

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

GlobeNewswire

a month ago

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Allogene Therapeutics, Inc. (ALLO): Among the Rising Penny Stocks to Invest In Now

Insider Monkey

a month ago

Allogene Therapeutics, Inc. (ALLO): Among the Rising Penny Stocks to Invest In Now

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

GlobeNewswire

2 months ago

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence

GlobeNewswire

2 months ago

Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence

IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains?

Zacks

2 months ago

IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains?

Allogene Therapeutics, Inc. (ALLO): Short Seller Sentiment is Bearish on This Cancer Stock

Insider Monkey

2 months ago

Allogene Therapeutics, Inc. (ALLO): Short Seller Sentiment is Bearish on This Cancer Stock

Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?

Zacks

2 months ago

Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?

Allogene Therapeutics Second Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.53 loss in 2Q 2023)

Simply Wall St.

3 months ago

Allogene Therapeutics Second Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.53 loss in 2Q 2023)

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2

Zacks

3 months ago

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2

MT Newswires

3 months ago

Truist Adjusts Allogene Therapeutics' PT to $14 From $17, Keeps Buy Rating

MT Newswires

3 months ago

Oppenheimer Adjusts Allogene Therapeutics Price Target to $11 From $13, Maintains Outperform Rating

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

GlobeNewswire

3 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Associated Press Finance

3 months ago

Allogene Therapeutics: Q2 Earnings Snapshot

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

GlobeNewswire

3 months ago

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

GlobeNewswire

4 months ago

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

GlobeNewswire

5 months ago

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

With 56% institutional ownership, Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst the big guns

Simply Wall St.

5 months ago

With 56% institutional ownership, Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a favorite amongst the big guns

Allogene Therapeutics, Inc. (ALLO): Are Analysts Bullish About the Potential of This Small-Cap Stock?

Insider Monkey

5 months ago

Allogene Therapeutics, Inc. (ALLO): Are Analysts Bullish About the Potential of This Small-Cap Stock?

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

GlobeNewswire

5 months ago

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?

Zacks

5 months ago

Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?

MT Newswires

6 months ago

Piper Sandler Starts Allogene Therapeutics With Overweight Rating, $11 Price Target

Insiders Pour Millions Into These 2 ‘Strong Buy’ Stocks

TipRanks

6 months ago

Insiders Pour Millions Into These 2 ‘Strong Buy’ Stocks

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

GlobeNewswire

6 months ago

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

MT Newswires

6 months ago

Oppenheimer Trims Allogene Therapeutics Price Target to $13 From $14, Maintains Outperform Rating

MT Newswires

6 months ago

HC Wainwright Adjusts Price Target on Allogene Therapeutics to $9 From $10, Keeps Buy Rating

Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag

Zacks

6 months ago

Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag

MT Newswires

6 months ago

Stifel Adjusts Price Target on Allogene Therapeutics to $4.60 From $4.40, Keeps Hold Rating

MT Newswires

6 months ago

B. Riley Adjusts Price Target on Allogene Therapeutics to $7 From $10, Keeps Buy Rating

GuruFocus.com

6 months ago

Allogene Therapeutics Inc (ALLO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...

MT Newswires

6 months ago

Allogene Therapeutics Prices $110 Million Offering

Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates

Zacks

6 months ago

Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

GlobeNewswire

6 months ago

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

Associated Press Finance

6 months ago

Allogene Therapeutics: Q1 Earnings Snapshot

MT Newswires

6 months ago

Allogene Therapeutics Q1 Loss Narrows, Revenue Declines

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

GlobeNewswire

6 months ago

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?

Zacks

6 months ago

CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

GlobeNewswire

6 months ago

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

MT Newswires

7 months ago

Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

GlobeNewswire

7 months ago

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

7 months ago

Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

7 months ago

Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?

Allogene Therapeutics Announces Q2 Investor Conference Participation

GlobeNewswire

7 months ago

Allogene Therapeutics Announces Q2 Investor Conference Participation

How Allogene (ALLO) Stock Stands Out in a Strong Industry

Zacks

7 months ago

How Allogene (ALLO) Stock Stands Out in a Strong Industry

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Simply Wall St.

7 months ago

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript

Insider Monkey

8 months ago

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript

Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss

Zacks

8 months ago

Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss

Thomson Reuters StreetEvents

8 months ago

Q4 2023 Allogene Therapeutics Inc Earnings Call

GuruFocus.com

8 months ago

Allogene Therapeutics Inc (ALLO) Reports Q4 and Full Year 2023 Financials, Forecasts Cash ...

Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates

Zacks

8 months ago

Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates

Associated Press Finance

8 months ago

Allogene Therapeutics: Q4 Earnings Snapshot

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

GlobeNewswire

8 months ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology

Zacks

8 months ago

Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology

Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease

BioPharma Dive

8 months ago

Allogene taps Arbor in pursuit of ‘off-the-shelf’ CAR-T therapies for autoimmune disease

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

GlobeNewswire

8 months ago

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

Allogene Therapeutics (ALLO)'s Technical Outlook is Bright After Key Golden Cross

Zacks

8 months ago

Allogene Therapeutics (ALLO)'s Technical Outlook is Bright After Key Golden Cross

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

GlobeNewswire

8 months ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

GlobeNewswire

9 months ago

Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia

GlobeNewswire

9 months ago

Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia

4 Eye-Catching Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

Motley Fool

9 months ago

4 Eye-Catching Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

LendingClub (LC) Q4 Earnings and Revenues Beat Estimates

Zacks

10 months ago

LendingClub (LC) Q4 Earnings and Revenues Beat Estimates

Calculating The Intrinsic Value Of MeridianLink, Inc. (NYSE:MLNK)

Simply Wall St.

10 months ago

Calculating The Intrinsic Value Of MeridianLink, Inc. (NYSE:MLNK)

Peapack-Gladstone (PGC) Misses Q4 Earnings and Revenue Estimates

Zacks

10 months ago

Peapack-Gladstone (PGC) Misses Q4 Earnings and Revenue Estimates

Business First Bancshares, Inc. (NASDAQ:BFST) Q4 2023 Earnings Call Transcript

Insider Monkey

10 months ago

Business First Bancshares, Inc. (NASDAQ:BFST) Q4 2023 Earnings Call Transcript

Loma Negra Compania Industrial Argentina S.A. Sponsored ADR (LOMA) Stock Sinks As Market Gains: What You Should Know

Zacks

10 months ago

Loma Negra Compania Industrial Argentina S.A. Sponsored ADR (LOMA) Stock Sinks As Market Gains: What You Should Know

Bitfarms Purchases Land in Yguazu, Paraguay in Support of Transformative Fleet Upgrade & 2024 Target of 21 EH/s

GlobeNewswire

10 months ago

Bitfarms Purchases Land in Yguazu, Paraguay in Support of Transformative Fleet Upgrade & 2024 Target of 21 EH/s

Solar Stocks Have Sunk. Why an Analyst Says to Buy Sunnova and Enphase.

Barrons.com

10 months ago

Solar Stocks Have Sunk. Why an Analyst Says to Buy Sunnova and Enphase.

Varex Schedules First Quarter Fiscal Year 2024 Earnings Release and Conference Call

Business Wire

10 months ago

Varex Schedules First Quarter Fiscal Year 2024 Earnings Release and Conference Call

First Watch Announces Acquisition of Tulsa-Area Franchise Location

GlobeNewswire

10 months ago

First Watch Announces Acquisition of Tulsa-Area Franchise Location

Dynex Capital, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call

Business Wire

10 months ago

Dynex Capital, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call

Kaman (KAMN) Soars 100.9%: Is Further Upside Left in the Stock?

Zacks

10 months ago

Kaman (KAMN) Soars 100.9%: Is Further Upside Left in the Stock?

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

GuruFocus.com

10 months ago

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

KKR Real Estate Finance Trust Inc. to Announce Fourth Quarter 2023 Results

Business Wire

10 months ago

KKR Real Estate Finance Trust Inc. to Announce Fourth Quarter 2023 Results

Huntsman Updates Fourth Quarter 2023 Outlook; To Discuss Fourth Quarter 2023 Results on February 22, 2024; Results to be Released After Market Close on February 21, 2024

PR Newswire

10 months ago

Huntsman Updates Fourth Quarter 2023 Outlook; To Discuss Fourth Quarter 2023 Results on February 22, 2024; Results to be Released After Market Close on February 21, 2024

FirstEnergy Ohio Utilities’ Competitive Bidding Process Auction: Applications From Prospective Bidders Due No Later Than Thursday, January 25, 2024

Business Wire

10 months ago

FirstEnergy Ohio Utilities’ Competitive Bidding Process Auction: Applications From Prospective Bidders Due No Later Than Thursday, January 25, 2024

Insteel Industries Reports First Quarter 2024 Results

Business Wire

10 months ago

Insteel Industries Reports First Quarter 2024 Results

Analyst Approved: 3 Stocks Wall Street Insiders Are Whispering About

InvestorPlace

10 months ago

Analyst Approved: 3 Stocks Wall Street Insiders Are Whispering About

Fidelity National (FIS) Up 14% in 3 Months: More Room to Run?

Zacks

10 months ago

Fidelity National (FIS) Up 14% in 3 Months: More Room to Run?

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

GlobeNewswire

10 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Molina Healthcare (MOH) Up 26.9% in 6 Months: What Lies Ahead?

Zacks

10 months ago

Molina Healthcare (MOH) Up 26.9% in 6 Months: What Lies Ahead?

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Zacks

10 months ago

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Gladstone Land Announces Gain on Sale of Florida Farm

ACCESSWIRE

10 months ago

Gladstone Land Announces Gain on Sale of Florida Farm

Surging Earnings Estimates Signal Upside for SMART Global Holdings, Inc. (SGH) Stock

Zacks

10 months ago

Surging Earnings Estimates Signal Upside for SMART Global Holdings, Inc. (SGH) Stock

Does the Market Have Doubts About Gray Television’s (GTN) Future?

Insider Monkey

10 months ago

Does the Market Have Doubts About Gray Television’s (GTN) Future?

Are Alarm.com Holdings, Inc. (NASDAQ:ALRM) Investors Paying Above The Intrinsic Value?

Simply Wall St.

10 months ago

Are Alarm.com Holdings, Inc. (NASDAQ:ALRM) Investors Paying Above The Intrinsic Value?

Share on Social Networks: